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Massively Parallel Sequencing (MPS) allows sequencing
of entire exomes and genomes to now be done at rea-
sonable cost, and its utility for identifying genes respon-
sible for rare Mendelian disorders has been
demonstrated. However, for a complex disease such as
the common cancers, study designs need to accommo-
date substantial degrees of locus, allelic, and phenotypic
heterogeneity, as well as complex relationships between
genotype and phenotype. Such considerations include
careful selection of samples for sequencing and a well-
developed strategy for identifying the few “true” disease
susceptibility genes from among the many irrelevant
g e n e st h a tw i l lb ef o u n dt oh a r b o rr a r ev a r i a n t s .T o
examine these issues we have performed simulation-
based analyses in order to compare several strategies for
MPS sequencing in complex disease. Factors examined
include genetic architecture, sample size, number and
relationship of individuals selected for sequencing, and a
variety of filters based on variant type, multiple observa-
tions of genes and concordance of genetic variants
within pedigrees. A two-stage design was assumed
where genes from the MPS analysis of high-risk families
are evaluated in a secondary screening phase of a larger
set of probands with more modest family histories.
Designs were evaluated using a cost function that
assumed the cost of sequencing the whole exome was
400 times that of sequencing a single candidate gene.
Results indicate that while requiring variants to be iden-
tified in multiple pedigrees and/or in multiple indivi-
duals in the same pedigree are effective strategies for
reducing false positives, there is a danger of over-filter-
ing so that most true susceptibility genes are missed. In
most cases, sequencing more than two individuals per
pedigree results in reduced power without any benefit in
terms of reduced overall cost. Further, our results sug-
gest that although no single strategy is optimal, simula-
tions can provide important guidelines for study design.
Examples in familial breast cancer and melanoma will
be presented to illustrate these points.
Author details
1Department of Dermatology, University of Utah School of Medicine, Salt
Lake City, UT, USA.
2Huntsman Cancer Institute and Department of
Oncological Sciences, University of Utah, Salt Lake City, UT, USA.
3Department of Pathology, University of Melbourne, VIC 3010, Australia.
Published: 12 April 2012
doi:10.1186/1897-4287-10-S2-A38
Cite this article as: Feng et al.: Design considerations for massively
parallel sequencing studies of common familial cancers. Hereditary
Cancer in Clinical Practice 2012 10(Suppl 2):A38.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
1Department of Dermatology, University of Utah School of Medicine, Salt
Lake City, UT, USA
Full list of author information is available at the end of the article
Feng et al. Hereditary Cancer in Clinical Practice 2012, 10(Suppl 2):A38
http://www.hccpjournal.com/content/10/S2/A38
© 2012 Feng et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.